Virbac S.A.
Virbac S.A. (VRBCF) Revenue
Annual & quarterly revenue history · segment & region breakdown
VRBCF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsVirbac S.A. trailing twelve-month (TTM) revenue is $2.86B, an increase of 4.78% year-over-year from $1.46B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.46B | +$0.07B | +4.78% |
| 2024-12-31 | $1.40B | +$0.15B | +12.07% |
| 2023-12-31 | $1.25B | +$0.03B | +2.53% |
| 2022-12-31 | $1.22B | +$0.15B | +14.31% |
| 2021-12-31 | $1.06B | +$0.13B | +13.89% |
| 2020-12-31 | $0.93B | -$0.00B | -0.44% |
| 2019-12-31 | $0.94B | +$0.07B | +7.99% |
| 2018-12-31 | $0.87B | +$0.01B | +0.82% |
| 2017-12-31 | $0.86B | -$0.01B | -1.14% |
| 2016-12-31 | $0.87B | +$0.02B | +2.25% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare VRBCF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Virbac S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Virbac S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Virbac S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
VRBCF revenue · 4 questionsVRBCF's trailing twelve-month (TTM) revenue is $2.86B. That is an increase of 4.78% year-over-year from $1.46B in FY2025.
▸ Source: FMP · Virbac S.A. SEC filings · GAAP · Virbac S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026